(Q42958346)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Jyh-Chin Yang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Po-Ren Hsueh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

J-C Yang

1

1 reference

11 November 2017

P-R Hsueh

3

1 reference

11 November 2017

publication date

25 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Microbiology & Infectious Diseases

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

1369-1375

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20658256%20AND%20SRC:MED&resulttype=core&format=json

Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate

8 February 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10096-010-1009-9

Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10096-010-1009-9

Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10096-010-1009-9

Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents.

21 January 2018

1 reference

12 December 2020

Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.

1 reference

12 December 2020

In vitro activity of gemifloxacin against Helicobacter pylori

1 reference

12 December 2020

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

1 reference

12 December 2020

Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea

1 reference

12 December 2020

Quinolone resistance in Helicobacter pylori isolates in Germany

1 reference

12 December 2020

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

1 reference

12 December 2020

H pylori antibiotic resistance: prevalence, importance, and advances in testing

1 reference

12 December 2020

Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection

1 reference

12 December 2020

Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan

1 reference

12 December 2020

Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium

1 reference

12 December 2020

In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan

1 reference

12 December 2020

Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.

1 reference

12 December 2020

In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children

1 reference

12 December 2020

Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori

1 reference

12 December 2020

Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori

1 reference

12 December 2020

The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance

1 reference

12 December 2020

Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan

1 reference

12 December 2020

Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection

1 reference

12 December 2020

Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan

1 reference

12 December 2020

Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication

1 reference

12 December 2020

Genetic analysis of the cytotoxin-associated gene and the vacuolating toxin gene in Helicobacter pylori strains isolated from Taiwanese patients

1 reference

12 December 2020

Eradication therapy for Helicobacter pylori

1 reference

12 December 2020

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates

1 reference

12 December 2020

Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.

1 reference

12 December 2020

Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility

1 reference

12 December 2020

Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial

1 reference

12 December 2020

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

12 December 2020

Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients

1 reference

12 December 2020

Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers

1 reference

12 December 2020